Summary
Eli Lilly and Company (LLY) filed an 8-K on August 3, 2021, to report its financial results for the quarter ended June 30, 2021. The filing primarily consists of a press release (Exhibit 99.1) which contains the company's unaudited financial results for the period. Investors should review this press release for details on the company's operational and financial performance during the second quarter of 2021. This report serves as a notification of the release of these results, with the detailed financial information contained within the attached exhibit.
Key Highlights
- 1The 8-K filing on August 3, 2021, pertains to Eli Lilly's second-quarter 2021 financial results.
- 2The core of the filing is Exhibit 99.1, a press release dated August 3, 2021.
- 3This press release contains unaudited financial results for the quarter ended June 30, 2021.
- 4The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- 5Investors seeking details on LLY's Q2 2021 performance should consult the attached press release.
- 6No significant new business events or regulatory actions are detailed in the 8-K itself, beyond the financial results announcement.
Frequently Asked Questions
The main purpose of this 8-K filing is to announce and provide Eli Lilly and Company's unaudited financial results for the second quarter ended June 30, 2021, through an attached press release.
The detailed financial information for Q2 2021 is contained within Exhibit 99.1, which is a press release dated August 3, 2021, attached to this 8-K filing.
No, the information in Item 2.02 of this 8-K, including the attached press release, is being furnished and is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section unless expressly incorporated by reference into other filings.
This particular 8-K filing focuses solely on the reporting of financial results for the second quarter of 2021. It does not contain information about new drug approvals or other significant business developments; those would typically be disclosed in separate filings or press releases.